Vaxart, Inc.

NASDAQ:VXRT

Biotechnology

Healthcare
$0.53 -1.75%

-$0.01 today

Market cap
$129.30M
Beta
1.09
P/E (TTM)
3.6
EPS (TTM)
$0.15
52W Low $0.26High $0.84

Volume 0.12M

Average 0.41M

VXRT Pre-Tax Margin

Income before tax as a percentage of revenue.

Vaxart, Inc.NASDAQ: VXRT

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to 13.3%

Pre-tax margin was 13.3% in Q1 FY2026, up 87.5 pp from a year earlier. On a trailing-twelve-month basis it was 14.7%, up 136.7 pp year over year. Over 3 fiscal years it widened by 100652.9 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
13.3%-39.9 pp QoQ
Last fiscal yearDec 2025
7.1%+239.4 pp YoY
LTMMar 2026
14.7%+136.7 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+87.5 pp——
1 year+239.4 pp——
3 years+100652.9 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
7.1%
Year-over-year change
+239.4pp

Pre-Tax Margin vs competitors

How VXRT compares with its peers on the latest reported figures

  • VXRT's LTM Mar 2026 pre-tax margin of 14.7% is the 2nd highest of the 5 companies compared; the peer median is -1777.2%.
  • Its year-over-year change of +136.7 pp is the lowest of 5, against a peer median of +1424.2 pp.
  • Over three fiscal years its change of +100652.9 pp compares with a peer median of +228.8 pp.
VXRT Competitors Peer median
Pre-Tax Margin for VXRT and competitors
Company Period LTM level YoY 3-year change
FBIOFortress Biotech, Inc.LTM Mar 2026201.4% +385.1 pp+228.8 pp
VXRTVaxart, Inc.LTM Mar 202614.7% +136.7 pp+100652.9 pp
TCRXTScan Therapeutics, Inc.LTM Mar 2026-1360.6% +1613.5 pp-767.6 pp
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-2193.7% +1234.9 pp—
CBUSCibus, Inc.LTM Mar 2026-2426.4% +3995.7 pp+7126.5 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding VXRT) -1777.2%+1424.2 pp+228.8 pp

Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue892K107K7.38M28.7M237.26M
Cost of Revenue48.75M04.5M00
Gross Profit(47.86M)107K2.88M28.7M237.26M
Gross Margin-5365.1%100.0%39.0%100.0%100.0%
Research & Development48.75M81.05M68.14M74.21M201.58M
Selling, General & Admin21.89M29.39M22.58M20.78M17.61M
Operating Expenses24.9M114.69M86.23M94.99M219.18M
Depreciation & Amortization2.43M5.81M8.62M8.85M8.58M
EBITDA(66.45M)(100.58M)(72.13M)(54.87M)28.21M
EBITDA Margin-7449.7%-94000.9%-977.5%-191.2%11.9%
Operating Income(72.75M)(114.59M)(83.35M)(66.29M)18.07M
Operating Margin-8156.1%-107090.7%-1129.5%-231.0%7.6%
Interest Income81K1.25M2.65M2.54M1.6M
Interest Expense1.48M1.31M1.45M2.97M2.82M
Other Income / Expenses2.39M6.9M1.14M(395K)(1.27M)
Income Before Tax(70.36M)(107.69M)(82.2M)(66.69M)16.8M
Pre-Tax Margin-7888.2%-100645.8%-1114.0%-232.4%7.1%
Income Tax Expense107K67K261K260K476K
Net Income(70.47M)(107.76M)(82.47M)(66.95M)16.33M
Net Margin-7900.2%-100708.4%-1117.6%-233.3%6.9%
EPS (Basic)(0.14)(0.22)(0.17)(0.14)0.07
EPS (Diluted)(0.14)(0.22)(0.17)(0.14)0.07
Weighted Avg Shares487.26M487.26M487.26M487.26M230.27M
Weighted Avg Shares (Diluted)487.26M487.26M487.26M487.26M230.35M

Vaxart, Inc.

NASDAQ:VXRT

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.